EGFR and non-small cell lung carcinoma: However, the efficacy of ICI therapy is limited in patients with EGFR-mutated NSCLC, specifically, the response rate in a phase II trial of nivolumab monotherapy in patients after resistance to EGFR-TKI therapy was 9.6% (5).